Cross-Sector entity
pharma is the sole category represented across all 1 tracked stories. GoodRx is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 12 original sources each. Collegium appears in 1 tracked Cross-Sector story from February 26, 2026.
1 verified story tracked
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. GoodRx is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 12 original sources each. Collegium appears in 1 tracked Cross-Sector story from February 26, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Collegium. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
